Cargando…
Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer
BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243642/ https://www.ncbi.nlm.nih.gov/pubmed/32476800 http://dx.doi.org/10.3748/wjg.v26.i19.2388 |
_version_ | 1783537443672162304 |
---|---|
author | Li, Zheng-Yan Wang, Xiao-Dong Li, Mou Liu, Xi-Jiao Ye, Zheng Song, Bin Yuan, Fang Yuan, Yuan Xia, Chun-Chao Zhang, Xin Li, Qian |
author_facet | Li, Zheng-Yan Wang, Xiao-Dong Li, Mou Liu, Xi-Jiao Ye, Zheng Song, Bin Yuan, Fang Yuan, Yuan Xia, Chun-Chao Zhang, Xin Li, Qian |
author_sort | Li, Zheng-Yan |
collection | PubMed |
description | BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC. METHODS: This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (n = 70) and a validation set (n = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram. RESULTS: Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation. CONCLUSION: A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC. |
format | Online Article Text |
id | pubmed-7243642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-72436422020-05-30 Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer Li, Zheng-Yan Wang, Xiao-Dong Li, Mou Liu, Xi-Jiao Ye, Zheng Song, Bin Yuan, Fang Yuan, Yuan Xia, Chun-Chao Zhang, Xin Li, Qian World J Gastroenterol Retrospective Study BACKGROUND: Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. AIM: To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC. METHODS: This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set (n = 70) and a validation set (n = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram. RESULTS: Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation. CONCLUSION: A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC. Baishideng Publishing Group Inc 2020-05-21 2020-05-21 /pmc/articles/PMC7243642/ /pubmed/32476800 http://dx.doi.org/10.3748/wjg.v26.i19.2388 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Li, Zheng-Yan Wang, Xiao-Dong Li, Mou Liu, Xi-Jiao Ye, Zheng Song, Bin Yuan, Fang Yuan, Yuan Xia, Chun-Chao Zhang, Xin Li, Qian Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title | Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title_full | Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title_fullStr | Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title_full_unstemmed | Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title_short | Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
title_sort | multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243642/ https://www.ncbi.nlm.nih.gov/pubmed/32476800 http://dx.doi.org/10.3748/wjg.v26.i19.2388 |
work_keys_str_mv | AT lizhengyan multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT wangxiaodong multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT limou multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT liuxijiao multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT yezheng multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT songbin multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT yuanfang multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT yuanyuan multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT xiachunchao multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT zhangxin multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer AT liqian multimodalradiomicsmodeltopredicttreatmentresponsetoneoadjuvantchemotherapyforlocallyadvancedrectalcancer |